RHA® 3 Versus Restylane-L® for Lip Augmentation

CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

May 11, 2022

Study Completion Date

September 7, 2022

Conditions
Lip AugmentationLip
Interventions
DEVICE

RHA 3

Investigational Product, RHA® 3 is a viscoelastic, sterile, non-pyrogenic, clear, colorless, homogenous, and biodegradable gel implant. It is formulated with sodium hyaluronic acid (NaHA) at a concentration of 23 mg/g obtained from bacterial fermentation using the Streptococcus equi bacterial strained, crosslinked with 1,4 butanediol diglycidyl ether (BDDE) and reconstituted in a physiological buffer (pH 7.3). RHA® 3 also contains 0.3% lidocaine hydrochloride to reduce pain on injection.

DEVICE

Restylane-L

Comparator Product, Restylane-L is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine.

Trial Locations (1)

34209

United States, Florida, Bradenton

All Listed Sponsors
lead

Teoxane SA

INDUSTRY

NCT04540913 - RHA® 3 Versus Restylane-L® for Lip Augmentation | Biotech Hunter | Biotech Hunter